

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Sarvetnick et al.
SERIAL NUMBER: 10/672,685 EXAMINER : Gailene Gabel
FILING DATE: September 26, 2003 ART UNIT : 1641
FOR: PANCREATIC PROGENITOR CELLS AND METHODS FOR
ISOLATING THE SAME

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form PTO-1449 (2 pages), in duplicate;
3. Copy of cited references: C21-54; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 18427-001 CON2. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Christina K. Stock, Reg. No. 45,899

Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.


Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: July 19, 2006



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Sarvetnick et al.
SERIAL NUMBER: 10/672,685 EXAMINER : Gailene Gabel
FILING DATE: September 26, 2003 ART UNIT : 1641
FOR: PANCREATIC PROGENITOR CELLS AND METHODS FOR
ISOLATING THE SAME

Mail Stop Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A4-A7 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Sarvetnick et al.
U.S.S.N.: 10/672,685

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 18427-001 CON2.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529

Christina K. Stock, Reg. No. 45,899

Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: July 19, 2006

TRA 2177463v.1

Express Mail No.: EV 538964949 US
Date of Deposit: July 19, 2006



Page 1 of 2
Attorney Docket No.: 18427-001 CON2

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/672,685	
				Filing Date		September 26, 2003	
				First Named Inventor		Sarvetnick	
				Group Art Unit		1641	
				Examiner Name		Gailene Gabel	
				Attorney Docket Number		18427-001 CON2	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A4	4,470,461	09/11/84	Stapp	166	273	
	*A5	5,122,464	06/16/92	Wilson et al.	435	172.3	
	*A6	5,681,587	10/28/97	Halberstadt et al.	424	562	
	*A7	5,824,544	10/20/98	Armentano et al.	435	320.1	
U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C21	Alarid et al., <i>Proc. Natl. Acad. Sci. USA</i> , 91(3):1074-1078 (1994)					
	C22	Berkner, <i>Curr. Top. Microbiol. Immunol.</i> , 158:39-66 (1992)					
	C23	Blau et al., <i>N. Engl. J. Med.</i> , 333(23):1554-1556 (1995)					
	C24	Blau et al., <i>Nat. Med.</i> , 3(6):612-613 (1997)					
	C25	Bottaro et al., <i>J. Biol. Chem.</i> , 268(13):9180-9183 (1993)					
	C26	Brinster et al., <i>Proc. Natl. Acad. Sci. USA</i> , 91(24):11303-11307 (1994)					
	C27	Brinster et al., <i>Proc. Natl. Acad. Sci. USA</i> , 91(24):11298-11302 (1994)					
	C28	Connelly et al., <i>Hum. Gene Ther.</i> , 6(2):185-193 (1995)					
	C29	Damjanov et al., <i>Lab. Invest.</i> , 55(5):588-592 (1986)					
	C30	Davis et al., <i>Nature</i> , 372(6503):263-266 (1994)					
	C31	Githens, <i>J. Ped. Gastroenterol. Nutr.</i> , 7(4):486-506 (1988)					

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C32	Gu et al., <i>Recent Progress Hormone Res.</i> , 49:161-165 (1994)
	C33	Gutniak et al., <i>N. Engl. J. Med.</i> , 326:1316-1322 (1992)
	C34	Hodgson, <i>BioTechnology</i> , 13:222-225 (1995)
	C35	Jaenisch, <i>Science</i> , 240:1468-1474 (1988)
	C36	Jolly, <i>Cancer Gene Ther.</i> , 1(1):51-64 (1994)
	C37	Jones, <i>Clin. Sci.</i> , 91(2):141-146 (1996)
	C38	Kalyani et al., <i>Dev. Biol.</i> , 186(2):202-223 (1997)
	C39	Kaneda et al., <i>Science</i> , 243:375-378 (1989)
	C40	Kerr-Conte et al., <i>Diabetes</i> , 45(8):1108-1114 (1996)
	C41	Kondo et al., <i>Cell</i> , 91(5):661-672 (1997)
	C42	Milos et al., <i>Genes Dev.</i> , 6(6):991-1004 (1992)
	C43	Movassat et al., <i>Diabete & Metabolisme (Paris)</i> , 21:365-370 (1995)
	C44	Peel, <i>Virus Vectors & Gene Therapy: Problems, Promises & Prospects</i> , (MBChB Special Study Module Project Report, Department of Microbiology & Immunology, University of Leicester, 1998) (downloaded 7/13/2006)
	C45	Potten et al., <i>Development</i> , 110:1001-1020 (1990)
	C46	Reynolds et al., <i>Dev. Biol.</i> , 175(1):1-13 (1996)
	C47	Ricciardelli et al., <i>In Vitro Cell Dev. Biol.</i> , 25(11):1016-1024 (1989)
	C48	Schieder et al., <i>Nat. Genetics</i> , 18(2):180-183 (1998)
	C49	Snyder et al., <i>Nat. Genetics</i> , 16(3):270-275 (1997)
	C50	Spangrude et al., <i>Science</i> , 241:58-62 (1988)
	C51	Stemple et al., <i>Cell</i> , 71(6):973-985 (1992)
	C52	Travis, <i>Science</i> , 259:1829 (1993)
	C53	Vinter-Jensen et al., <i>Gastroenterol.</i> , 113(4):1367-1374 (1997)
	C54	Wu et al., <i>J. Biol. Chem.</i> , 264(29):16985-16987 (1989)

* By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A4-A7 are not submitted.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.